Alectinib-a new chapter in the management of ALK-positive lung cancer.

about

The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK

P2860

Q38705578-7CA3686C-D1FA-471A-8722-209139239962 Q41382674-2EB383BE-B420-4306-99AC-05ADAF5D0AFC

P2860

Alectinib-a new chapter in the management of ALK-positive lung cancer.

Item

http://www.wikidata.org/entity/Q42434572

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Alectinib-a new chapter in the management of ALK-positive lung cancer.

@en

Alectinib-a new chapter in the management of ALK-positive lung cancer.

@nl

type

Item

label

Alectinib-a new chapter in the management of ALK-positive lung cancer.

@en

Alectinib-a new chapter in the management of ALK-positive lung cancer.

@nl

prefLabel

Alectinib-a new chapter in the management of ALK-positive lung cancer.

@en

Alectinib-a new chapter in the management of ALK-positive lung cancer.

@nl

P1476

Alectinib-a new chapter in the management of ALK-positive lung cancer.

@en

P2093

Justin F Gainor

http://www.w3.org/2001/XMLSchema#string

P2860

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

ALK in lung cancer: past, present, and future.

P304

343-346

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/TLCR.2016.03.05

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27411885

http://www.w3.org/2001/XMLSchema#string

P932

4931141

http://www.w3.org/2001/XMLSchema#string

Alectinib-a new chapter in the management of ALK-positive lung cancer.

about

P2860

P2860

Alectinib-a new chapter in the management of ALK-positive lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932